Safety and Efficacy of Ciclesonide in Pediatric Patients (6 to 11 Years of Age) With Seasonal Allergic Rhinitis (BY9010/M1-417)

Completed · Phase 3

Conditions studied: Hay Fever, Seasonal Allergic Rhinitis

In brief

The aim of the study is to determine the efficacy and safety of ciclesonide nasal spray in children with seasonal allergic rhinitis. Ciclesonide will be administered intranasally at two dose levels once daily. The study consists of a baseline period (1 to 3 weeks) and a treatment period (2 weeks).

Key facts

Study ID
NCT00305487
Run by
AstraZeneca
People needed
660
Starts
2006-03-01
Expected to finish
2006-10-01
Last updated by the study team
2016-11-30

Who can join

Age: 6 and older, up to 11. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.